Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

2025-04-22 11:46:08 ET

Summary

• Northwest Biotherapeutics is awaiting UK approval for DCVax-L, with a recent 40% share price spike due to speculation of imminent drug approval, in my opinion.
• Despite promising glioblastoma trial results, NWBO faces financial instability, heavy dilution, and an uncertain market size, making it a risky investment.
• Ongoing litigation over alleged stock spoofing could potentially bring a financial windfall, but its outcome remains uncertain.
• With a $500 million valuation and no approved product, NWBO's resilience is notable, but I maintain a "Sell" sentiment due to high risks.

Topline Summary and Update

Northwest Biotherapeutics, Inc. ( NWBO ) is one of those undying contenders in the cell therapy space, having been stagnated in the purgatory between publishing a nominally positive, though by no means unimpeachable, phase 3 trial in glioblastoma several years ago. They, and shareholders, have been anxiously awaiting notice of approval from the United Kingdom regulators since late 2023. Heading into the Easter weekend, the company saw a massive spike in share price, a 40% increase, presumably due to speculation of an announcement about an approval decision that is long overdue (per the UK's stated goals)....

Read the full article on Seeking Alpha

For further details see: